Home Cart Sign in  
Chemical Structure| 75330-75-5 Chemical Structure| 75330-75-5

Structure of Lovastatin
CAS No.: 75330-75-5

Chemical Structure| 75330-75-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lovastatin is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.

Synonyms: Mevinolin; Monacolin K; Altoprev

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lovastatin

CAS No. :75330-75-5
Formula : C24H36O5
M.W : 404.54
SMILES Code : CC[C@H](C)C(O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(O3)=O)[C@@]12[H])=O
Synonyms :
Mevinolin; Monacolin K; Altoprev
MDL No. :MFCD00072164
InChI Key :PCZOHLXUXFIOCF-BXMDZJJMSA-N
Pubchem ID :53232

Safety of Lovastatin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H351-H361
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
iPSC-ECs 1 μM 1 week To evaluate the effect of lovastatin on LMNA iPSC-ECs function, results showed that lovastatin improved endothelial cell function, increased KLF2 and eNOS expression, and enhanced NO production and tube formation. PMC7557117
iPSC-CMs 1 μM 1 week To evaluate the effect of lovastatin on LMNA iPSC-CMs function, results showed that when co-cultured with iPSC-ECs, lovastatin improved cardiomyocyte function, enhancing contractility and relaxation. PMC7557117
LS174T cells 10 µM 2 hours To evaluate the accumulation and conversion rate of Lovastatin in LS174T cells, results showed that XZK and F1 significantly increased the accumulation and conversion rate of LvA. PMC6289385
HepG2 cells 10 µM 2 hours To evaluate the accumulation and conversion rate of Lovastatin in HepG2 cells, results showed that XZK and F1 significantly increased the accumulation and conversion rate of LvA. PMC6289385
MOC1 cells 500 nM or less 120 hours Lovastatin inhibited MOC1 cell proliferation and enhanced T-cell-mediated killing of tumor cells. PMC9853267
TC-1 cells 500 nM or less 48 hours Lovastatin inhibited TC-1 cell proliferation and enhanced T-cell-mediated killing of tumor cells. PMC9853267
MDA-MB-231 1 μM 48 h Inhibited stemness properties including sphere formation and self-renewal capacity in TNBC MDA-MB-231 and 4T1 cells PMC11008279
4T1 1 μM 48 h Inhibited stemness properties including sphere formation and self-renewal capacity in TNBC MDA-MB-231 and 4T1 cells PMC11008279
MDA-MB-453 1 μM 48 h No significant effect on stemness properties in non-TNBC MDA-MB-453 cells PMC11008279

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Hypercholesterolemia model Intraperitoneal injection 10 mg/kg daily for 5 days To evaluate the effect of AGR2 on the lipid-lowering efficacy of Lovastatin, the results showed that AGR2 overexpression significantly reduced the lipid-lowering efficacy of Lovastatin PMC9622889
C57BL/6 mice High-fat diet-induced hyperlipidemia model Oral 40 mg Once daily for 6 months to 18 months To evaluate the pharmacokinetic behavior of Lovastatin in high-fat diet mice, results showed that XZK significantly increased the exposure of LvA and decreased the exposure of Lv. PMC6289385
Mice MOC1 tumor model Oral 10 mg/kg Once daily for 2 weeks Lovastatin combined with PD-1 blockade enhanced tumor control and extended survival, with rejection of tumors in 30% of mice treated with lovastatin plus anti-PD-1. PMC9853267
Nude mice Orthotopic tumor model of TNBC Intragastric administration 60 mg/kg Once daily for 3 weeks Lovastatin significantly inhibited tumor growth in mice inoculated with MDA-MB-231 SFCs but not MDA-MB-453 SFCs PMC11008279
C57BL/6J mice High-fat diet-induced obese mice Gastric irrigation 30 mg/kg/day Once daily for 6 weeks To study the effect of corylin on lipid metabolism in obese mice, results showed that corylin significantly reduced body weight, serum TC, TG, and LDL-c levels, and increased HDL-c levels. PMC6735373

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01047683 Hypertriglyceridemia Phase 3 Completed - -
NCT00256750 Kidney Transplantation ... More >> Chronic Kidney Failure Less << Phase 3 Completed - -
NCT01047501 Hypertriglyceridemia Phase 3 Completed - -
NCT00256750 - Completed - -
NCT01492361 Cardiovascular Diseases Phase 3 Completed - -
NCT02523001 - Completed - Italy ... More >> Department of Biomedical Sciences Human Oncology - Clinica Medica "A. Murri" Bari, Italy, 70124 Less <<
NCT00132717 Hypercholesterolemia Phase 3 Completed - -
NCT03739242 Hypercholesterolemia Not Applicable Completed - Italy ... More >> Policlinico S.Orsola - Malpighi Medicina Interna Borghi Bologna, Italy, 40138 Less <<
NCT01890967 - Completed - -
NCT03510715 Hypercholesterolemia Phase 3 Recruiting June 2020 United States, California ... More >> Investigational Site Number 8400004 Recruiting Los Angeles, California, United States, 90027 Austria Investigational Site Number 0400001 Recruiting Wien, Austria, 1090 Brazil Investigational Site Number 0760001 Recruiting Sao Paulo, Brazil, 05403-000 Canada Investigational Site Number 1240002 Recruiting Montreal, Canada, H3T 1C5 Investigational Site Number 1240001 Recruiting Quebec, Canada, G1V 4W2 Denmark Investigational Site Number 2080001 Recruiting Viborg, Denmark, 8800 France Investigational Site Number 2500001 Recruiting Bron Cedex, France, 69677 Italy Investigational Site Number 3800001 Recruiting Palermo, Italy, 90127 Mexico Investigational Site Number 4840006 Recruiting Oaxaca, Mexico, 68000 Netherlands Investigational Site Number 5280001 Recruiting Amsterdam, Netherlands, 1105 AZ Norway Investigational Site Number 5780001 Recruiting Oslo, Norway, 0373 Russian Federation Investigational Site Number 6430002 Recruiting Kemerovo, Russian Federation, 650002 Slovenia Investigational Site Number 7050001 Recruiting Ljubljana, Slovenia, 1000 Spain Investigational Site Number 7240001 Recruiting A Coruna, Spain, 15001 Taiwan Investigational Site Number 1580001 Recruiting Taipei, Taiwan, 112 Turkey Investigational Site Number 7920002 Recruiting Ankara, Turkey, 06500 Investigational Site Number 7920001 Recruiting Izmir, Turkey, 35040 Less <<
NCT03510884 Hypercholesterolaemia Phase 3 Recruiting March 2022 -
NCT00532311 Hypercholesterolemia Phase 3 Terminated(Overall profile of ... More >>the compound does not offer significant clinical advantage to patients over currently available lipid lowering agents) Less << - -
NCT03065491 Hypercholesterolemia Not Applicable Completed - Italy ... More >> S. Orsola-Malpighi University Hospital Bologna, BO, Italy, 40138 Less <<
NCT00986583 Pain Not Applicable Completed - United States, Ohio ... More >> Cleveland Clinic Foundation Cleveland, Ohio, United States, 44195 Less <<
NCT01890967 Hypercholesterolemia Phase 2 Completed - -
NCT02969070 Hypercholesterolemia ... More >> Endothelial Dysfunction Less << Phase 3 Unknown March 2017 Italy ... More >> University of Naples "Federico II" Recruiting Naples, Italy, 80131 Contact: Giuseppe Giugliano, MD, PhD    +390817462240    giuseppe.giugliano@unina.it    Sub-Investigator: Raffaele Izzo, MD          Sub-Investigator: Maurizio Galderisi, MD          Sub-Investigator: Giuseppe Giugliano, MD, PhD Less <<
NCT00986583 - Completed - -
NCT03425630 Hypercholesterolemia Not Applicable Completed - -
NCT02142569 Cholesterol Lowering Phase 2 Phase 3 Suspended(We were unable to pr... More >>ocure the supplement for this study.) Less << July 2018 United States, California ... More >> UCLA Center for Human Nutrition, 900 Veteran Avenue, WH 14-187 Los Angeles, California, United States, 90095 Less <<
NCT00726362 - Completed - Taiwan ... More >> Research Site Changhua, Taiwan Research Site Hualien, Taiwan Research Site Kaohsiung, Taiwan Research Site Pingtung, Taiwan Research Site Taichung, Taiwan Research Site Tainan, Taiwan Research Site Taipei, Taiwan Research Site Yun-Lin, Taiwan Less <<
NCT01807078 Coronary Artery Disease Phase 4 Unknown December 2017 Italy ... More >> Sapienza University Not yet recruiting Rome, Lazio, Italy, 00161 Contact: Francesco Pelliccia, MD    +39064997 ext 123    f.pelliccia@mclink.it    Contact: Giuseppe Marazzi, MD    +39064997 ext 123    md4151@mclink.it    Principal Investigator: Francesco Pelliccia, MD Less <<
NCT00452244 Lung Cancer Phase 2 Completed - Korea, Republic of ... More >> National Cancer Center, Korea Goyang-si, Gyeonggi-do, Korea, Republic of Less <<
NCT00145574 Hypercholesterolemia Phase 4 Completed - -
NCT00145574 - Completed - -
NCT00046358 Alzheimer Disease Phase 4 Completed - United States, Maryland ... More >> National Institute of Mental Health (NIMH) Bethesda, Maryland, United States, 20892 Less <<
NCT02518503 - Completed - -
NCT02603276 Hypercholesterolemia Not Applicable Completed - Italy ... More >> S. Orsola-Malpighi University Hospital Bologna, Italy, 40038 Less <<
NCT02518516 - Completed - Canada, British Columbia ... More >> Dept. of Anesthesiology, Pharmacology & Therapeutics (APT), University of British Columbia Vancouver, British Columbia, Canada, V6T 1Z3 Less <<
NCT00125125 Dyslipidemia Phase 4 Completed - United States, New Jersey ... More >> Novartis East Hanover, New Jersey, United States, 07936 Germany Investigative Centers, Germany Less <<
NCT01087632 Metabolic Syndrome Not Applicable Completed - Italy ... More >> Federico II University - Department of Internal Medicine Naples, Italy Less <<
NCT00730132 - Completed - -
NCT03216811 Hypercholesterolemia Phase 2 Completed - Italy ... More >> University Hospital of Ferrara Cona, Ferrara, Italy, 44124 Less <<
NCT00000463 Cardiovascular Diseases ... More >> Coronary Disease Heart Diseases Myocardial Ischemia Less << Phase 3 Completed - -
NCT02492464 Atherosclerosis Not Applicable Completed - Italy ... More >> S. Orsola-Malpighi University Hospital Bologna, BO, Italy, 40138 Less <<
NCT00730132 - Completed - -
NCT01269762 Healthy Volunteer Phase 4 Completed - Taiwan ... More >> National Taiwan University Hospital Taipei, Taiwan Less <<
NCT03470376 Hypercholesterolemia ... More >> Inflammation Atherosclerosis Less << Phase 4 Completed - -
NCT02658838 LOVASTATIN/TICAGRELOR [VA Drug... More >> Interaction] Less << Phase 4 Unknown September 2017 China, Beijing ... More >> Beijing Anzhen Hosipital Beijing, Beijing, China, 100000 Less <<
NCT01569854 - Withdrawn(Insufficient recruit... More >>ment) Less << March 2022 United States, Ohio ... More >> Ohio State University Medical Center Columbus, Ohio, United States, 43210 Less <<
NCT00718796 Cardiovascular Disease Phase 3 Completed - Canada, Ontario ... More >> Canadian College of Naturopathic Medicine Toronto, Ontario, Canada, M2K 1E2 Less <<
NCT01385020 Healthy Subjects Phase 4 Completed - Taiwan ... More >> National Taiwan University Hospital Taipei, Taiwan Less <<
NCT00000477 Atherosclerosis ... More >> Cardiovascular Diseases Coronary Disease Heart Diseases Hypercholesterolemia Myocardial Ischemia Less << Phase 2 Completed - -
NCT01569867 - Recruiting March 2022 United States, Ohio ... More >> The Ohio State University Medical Center Recruiting Columbus, Ohio, United States, 43210 Principal Investigator: Joseph P Kitzmiller, MD PhD          Sub-Investigator: Wolfgang Sadee, Dr rer nat          Sub-Investigator: Mitch Phelps, PhD          Sub-Investigator: Rebecca Jackson, MD Less <<
NCT02689934 Hypercholesterolemia Not Applicable Completed - Italy ... More >> Centro Dislipidemie Dip. Cardiotoracovasc ASST Grande Ospedale Metropolitano Niguarda Cà Granda Milano, Mi, Italy, 20162 Less <<
NCT00092846 Hypercholesterolemia Phase 3 Completed - -
NCT02964884 Neurofibromatosis Type 1 ... More >> Learning Disability Reading Disability NF1 Less << Phase 2 Recruiting June 2022 United States, Tennessee ... More >> Vanderbilt University Recruiting Nashville, Tennessee, United States Contact: Laura E. Cutting    615-875-1054 Less <<
NCT03340285 Cardiovascular Risk Factor Not Applicable Not yet recruiting April 2018 -
NCT00000512 Cardiovascular Diseases ... More >> Coronary Arteriosclerosis Coronary Disease Heart Diseases Myocardial Ischemia Less << Phase 3 Completed - -
NCT00000469 Cardiovascular Diseases ... More >> Carotid Stenosis Cerebral Arteriosclerosis Cerebrovascular Disorders Heart Diseases Vascular Diseases Less << Phase 2 Completed - -
NCT02862470 - Active, not recruiting July 7, 2020 -
NCT03504501 Impaired Synaptic Plasticity ... More >> Impaired Cognition Less << Phase 2 Recruiting June 2019 Germany ... More >> Technical University Munich Recruiting Munich, Germany, 81377 Contact: Volker Mall, Prof.    +49 (0)89 71009-233    volker.mall@kbo.de    Contact: Nikolai Jung, Dr.    +49 (0)89 71009-236    nikolai.jung@tum.de Less <<
NCT00741013 Lung Inflammation Early Phase 1 Completed - United States, Missouri ... More >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 Less <<
NCT00004346 Cerebrotendinous Xanthomatosis Phase 2 Unknown - United States, Oregon ... More >> Oregon Health and Science University Recruiting Portland, Oregon, United States, 97239-3098 Contact: Sonja Connor    503-494-7775    connors@ohsu.edu Less <<
NCT00116870 Atherosclerosis ... More >> Coronary Artery Disease Less << Phase 2 Phase 3 Completed - United States, California ... More >> Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine Los Angeles, California, United States, 90033 Less <<
NCT01250535 Healthy Volunteers ... More >> Drug Drug Interactions Less << Phase 1 Completed - United States, North Carolina ... More >> University of North Carolina, Clinical and Translational Research Center (CTRC) Chapel Hill, North Carolina, United States, 27599 Less <<
NCT03763175 Irritable Bowel Syndrome With ... More >>Constipation Less << Phase 2 Not yet recruiting January 1, 2020 United States, California ... More >> Cedars-Sinai Medical Center Not yet recruiting Los Angeles, California, United States, 90048 Contact: Tahli Singer-Englar    310-423-3792    tahli.singerenglar@cshs.org Less <<
NCT01361217 - Completed - -
NCT00062556 Intermittent Claudication ... More >> Peripheral Vascular Disease Less << Phase 3 Completed - -
NCT00345657 Hyperlipidemia ... More >> Mixed Hyperlipidemia Dyslipidemia Less << Phase 4 Completed - United States, Oklahoma ... More >> Family Medical Care of Tulsa Tulsa, Oklahoma, United States, 74136 Less <<
NCT00741013 - Completed - -
NCT01976936 Stroke Rhabdo... More >>myolysis Jaundice Less << Phase 2 Completed - United States, California ... More >> University of California, Los Angeles Stroke Network Los Angeles, California, United States, 90024 United States, Florida Jackson Memorial Hospital Miami, Florida, United States, 33136 University of Miami Miller School of Medicine Miami, Florida, United States, 33136 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, Massachusetts Brigham & Women's Hospital Boston, Massachusetts, United States, 02115 United States, New York Mount Sinai School of Medicine New York, New York, United States, 10029 United States, Pennsylvania The Hospital of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT01361217 Drug-Drug Interaction ... More >> Healthy Volunteers Less << Not Applicable Completed - -
NCT00721305 HIV Seropositivity Phase 2 Completed - Colombia ... More >> Group of Immunovirology, Research Universitary Center, University of Antioquia Medellin, Antioquia, Colombia Less <<
NCT00071266 Intermittent Claudication ... More >> Peripheral Vascular Disease Less << Phase 3 Completed - -
NCT00902668 Breast Cancer ... More >> Radiation Toxicity Less << Phase 2 Terminated(Slow accrual) - -
NCT00902668 - Terminated(Slow accrual) - -
NCT00689806 Severe Persistent Asthma Phase 1 Phase 2 Withdrawn(Study never opened) - -
NCT02998151 Fragile X Syndrome Phase 2 Enrolling by invitation July 2021 United States, Ohio ... More >> Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 Less <<
NCT00462280 - Completed - -
NCT00853580 Neurofibromatosis Type 1 Phase 2 Completed - United States, Alabama ... More >> The University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, California Children's Hospital Los Angeles Los Angeles, California, United States, 90027 United States, District of Columbia Children's National Medical Center Washington, District of Columbia, United States, 20010 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Maryland NIH Bethesda, Maryland, United States, 20892 United States, Massachusetts Children' Hospital Boston Boston, Massachusetts, United States, 02115 United States, Missouri Washington University - St. Louis Saint Louis, Missouri, United States, 63110 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19096 United States, Texas Childrens Medical Center - Univ. of Texas SW Medical Center Dallas, Texas, United States, 75235 United States, Utah University of Utah Salt Lake City, Utah, United States, 84132 Australia, New South Wales The Children's Hospital at Westmead Westmead, New South Wales, Australia, 2145 Less <<
NCT01110642 Syndromic Ichthyoses|CHILD Syn... More >>drome|Smith Lemli Opitz Syndrome|Conradi Syndrome Less << PHASE2 WITHDRAWN - -
NCT00243880 Stroke Phase 1 Completed - United States, New York ... More >> Columbia University Medical Center New York, New York, United States, 10032 Less <<
NCT03178526 Alveolar Bone Loss, Chronic Pe... More >>riodontitis, Lovestatin Gel, Regeneration Less << Phase 2 Phase 3 Completed - -
NCT00352599 Neurofibromatosis 1 Phase 1 Completed - United States, California ... More >> Semel Institute for Neuroscience and Human Behavior Los Angeles, California, United States, 90095 Less <<
NCT00462280 Precancerous Condition ... More >> Stage 0 Melanoma Stage I Melanoma Stage II Melanoma Less << Phase 2 Completed - United States, California ... More >> University of California Medical Center At Irvine-Orange Campus Orange, California, United States, 92868 United States, Florida H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, Utah Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 Less <<
NCT02563860 Rett Syndrome PHASE2 COMPLETED 2025-07-16 Montefiore Medical center, Bro... More >>nx, New York, 10467, United States Less <<
NCT02389868 Blood Platelets Proteome PHASE2 COMPLETED 2025-06-15 Centre de Recherche du CHUS, S... More >>herbrooke, Quebec, J1H 5N4, Canada Less <<
NCT00302952 Rheumatoid Arthritis Phase 2 Completed - United States, Alabama ... More >> University of Alabama Birmingham, Alabama, United States, 35294 United States, California University of California, San Francisco San Francisco, California, United States, 94143 United States, Colorado University of Colorado Aurora, Colorado, United States, 80095 United States, Illinois University of Chicago Medical Center Chicago, Illinois, United States, 60637 United States, Michigan Justus J. Fiechtner, MD, PLLC Lansing, Michigan, United States, 48910 United States, New York Feinstein Institute for Medical Research NS-LIJ Health System Manhasset, New York, United States, 11030 University of Rochester Rochester, New York, United States, 14642 United States, North Carolina Carolina Bone and Joint Charlotte, North Carolina, United States, 29425 Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Oklahoma Oklahoma Medical Research Foundation Oklahoma City, Oklahoma, United States, 73104 United States, Pennsylvania Altoona Center for Clinical Research Duncansville, Pennsylvania, United States, 16635 University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States, 15261 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29425 United States, Texas Baylor Research Institute Dallas, Texas, United States, 75231 United States, Utah University of Utah Salt Lake City, Utah, United States, 84132 Less <<
NCT00853580 - Completed - -
NCT00302952 - Completed - -
NCT00584012 - Terminated(Funding issues) - -
NCT00685685 Healthy Phase 1 Completed - Canada ... More >> Algorithme Pharma Montreal, Canada, H7V 4B4 Less <<
NCT00700921 Chronic Obstructive Pulmonary ... More >>Disease (COPD) Less << Phase 2 Completed - United States, Colorado ... More >> National Jewish Medical and Research Center Denver, Colorado, United States, 80206 Less <<
NCT00684723 Healthy Phase 1 Completed - Canada, Quebec ... More >> Algorithme Pharma Montreal, Quebec, Canada Less <<
NCT00584012 Any Cancer Br... More >>east Cancer Less << Phase 1 Terminated(Funding issues) - United States, Iowa ... More >> Holden Comprehensive Cancer Center Iowa City, Iowa, United States, 52242 Less <<
NCT00685685 - Completed - -
NCT00583102 Acute Myeloid Leukemia Phase 1 Phase 2 Terminated(Slow accrual, PI le... More >>ft institution) Less << - United States, Iowa ... More >> Holden Comprehensive Cancer Center Iowa City, Iowa, United States, 52242 Less <<
NCT00963664 Melanoma Mali... More >>gnant Melanoma Less << Phase 2 Withdrawn(Modifications will b... More >>e necessary before full IRB approval will be secured.) Less << December 2016 United States, Tennessee ... More >> NeoPlas Innovation Nashville, Tennessee, United States, 37027 Less <<
NCT00684723 - Completed - -
NCT00285857 Breast Cancer PHASE2 TERMINATED 2025-12-10 Stanford University Cancer Cen... More >>ter, Stanford, California, 94305, United States Less <<
NCT02603770 Lipid Metabolism Disorder Phase 1 Completed - United States, California ... More >> NRC Research Institute Orange, California, United States, 92868 Less <<
NCT00583102 - Terminated(Slow accrual, PI le... More >>ft institution) Less << - -
NCT00580970 Prostate Cancer Phase 2 Completed - United States, Virginia ... More >> Hunter Holmes McGuire Veterans Administration Medical Center Richmond, Virginia, United States, 23249 Massey Cancer Center/Virginia Commonwealth University Richmond, Virginia, United States, 23298 Southside Regional Medical Center Richmond, Virginia, United States, 23805 Less <<
NCT02642653 Fragile X Syndrome ... More >> Genetic Diseases Less << Phase 4 Completed - United States, California ... More >> UC Davis MIND Institute Sacramento, California, United States, 95817 Less <<
NCT00580970 - Completed - -
NCT00585052 Ovarian Cancer Phase 2 Terminated(Slow accrual, PI le... More >>ft the institution) Less << - United States, Iowa ... More >> Holden Comprehensive Cancer Center Iowa City, Iowa, United States, 52327 Less <<
NCT00585052 - Terminated(Slow accrual, PI le... More >>ft the institution) Less << - -
NCT01346670 Healthy Volunteer Phase 4 Completed - Taiwan ... More >> Taipei Medical University - WanFang Hospital Taipei, Taiwan Less <<
NCT01527669 Healthy Subjects Phase 4 Completed - Taiwan ... More >> National Taiwan University Hospital Taipei, Taiwan Less <<
NCT01478828 Prostate Cancer TERMINATED 2013-04-08 The Sidney Kimmel Comprehensiv... More >>e Cancer Center at Johns Hopkins, Baltimore, Maryland, 21231, United States Less <<
NCT02680379 Fragile X Syndrome Phase 2 Completed - Canada, Quebec ... More >> Centre de Recherche du CHUS Sherbrooke, Quebec, Canada, J1H 5N4 Less <<
NCT03242499 Parkinson Disease Phase 2 Recruiting December 31, 2019 Taiwan ... More >> National Taiwan University Hospital Recruiting Taipei, Taiwan, 100 Contact: Chin-Hsien Lin, MD,PhD    886-2-3123456 ext 65335    chlin@ntu.edu.tw    Principal Investigator: Chin-Hsien Lin, MD,PhD Less <<
NCT01478828 Prostate Cancer TERMINATED 2013-04-08 The Sidney Kimmel Comprehensiv... More >>e Cancer Center at Johns Hopkins, Baltimore, Maryland, 21231, United States Less <<
NCT00285857 Breast Cancer PHASE2 TERMINATED 2025-12-10 Stanford University Cancer Cen... More >>ter, Stanford, California, 94305, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.47mL

0.49mL

0.25mL

12.36mL

2.47mL

1.24mL

24.72mL

4.94mL

2.47mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories